Embecta Securities Fraud Class Actions
Analysis based on 304 articles · First reported Jun 16, 2026 · Last updated Jul 24, 2026
The multiple class action lawsuits against Embecta, alleging securities fraud and misleading statements, have significantly damaged investor confidence. The company's stock price plummeted by nearly 58% following the announcement of missed guidance and lowered outlook, indicating a strong negative market reaction to the perceived corporate misconduct and financial underperformance. This event highlights the risks associated with investing in companies that may not accurately represent their financial health and product performance.
Multiple law firms, including Pomerantz LLP, Rosen Law Firm, Bleichmar Fonti & Auld LLP, Glancy Prongay & Murray, DJS Law Group, The Schall Law Firm, and Robbins LLP, have filed class action lawsuits against Embecta Corp. The lawsuits allege that Embecta and its officers engaged in securities fraud by making false and misleading statements about the company's financial performance and the strength of its insulin pen needle sales. On May 5, 2026, Embecta announced its second quarter 2026 financial results, revealing that it missed its guidance and lowered its outlook for the fiscal year, with revenue declining over 14% due to weakness in pen needle sales. This news caused Embecta's stock price to drop by nearly 58%, damaging investors. The lawsuits encourage affected investors to join the class actions, with a lead plaintiff deadline of August 17, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard